Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesGenetic & Molecular TestingAetna RET Proto-Oncogene Testing Coverage | OpenPa…
    Ask Trek AI about this page
    CurrentAetnaPolicy 0319

    RET Proto-Oncogene Testing

    Customize your policy alerts

    Sign up for Aetna Policy 0319 alerts

    Get alerted when Policy 0319 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs medical necessity and coverage criteria for germline RET gene testing (point mutation sequencing) primarily for evaluation of inherited medullary thyroid carcinoma/MEN2 and related indications for Aetna members.

    Policy Summary
    PayerAetna
    PolicyRET Proto-Oncogene Testing
    Policy CodePolicy 0319
    Change TypeNo material change
    Effective DateMar 18, 1999
    Last ReviewMay 8, 2023
    Next Review DateMar 14, 2024
    Key ActionObtain prior authorization when billing the listed molecular pathology or related procedure codes and document that the member meets one of the specified high‑risk criteria.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    100%reported test performance for identifying inherited MTC risk

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    25%
    proportion of MTC from familial syndromes
    11-13%germline mutations in SPP
    5,031patients in SPP review

    Coverage and Medical Necessity Criteria

    inv-01: Medically Necessary Indications — Covered when ANY of the following high-risk criteria are met:

    Covered when ANY of the following high-risk criteria are met:

    High-risk indications for germline RET testing: Members who meet any of the following: 1) First-degree relative (parent, full-sibling, child) with medullary thyroid carcinoma (MTC). 2) First- or second-degree relative with a known germline RET mutation (testing strategy: test for specific familial mutation). 3) Member has any of the following: C-cell hyperplasia; two or more endocrine tumors; Hirschsprung disease; MTC; paraganglioma; parathyroid carcinoma; or pheochromocytoma.

    Sequencing of the RET gene may be considered.

    inv-02: Diagnostic testing in apparent sporadic MTC

    Diagnostic testing for sporadic MTC: Diagnostic testing for germline point mutations in the RET gene is medically necessary for members with apparently sporadic medullary thyroid carcinoma.

    inv-03: Germline testing frequency and definition in SPP

    Evidence and considerations for germline testing in pheochromocytoma/paraganglioma

    Definition of sporadic tumor used in studies: Sporadic pheochromocytoma/paraganglioma (SPP) was defined by ALL of: absence of a family history of pheochromocytoma/paraganglioma; absence of syndromic features; absence of bilateral disease; and absence of metastatic disease.

    From systematic review inclusion criteria.

    Tests for germline point mutations in the RET gene are considered experimental and investigational (not covered) for indications other than those specifically listed as medically necessary in this policy. The policy explicitly cites non-small cell lung cancer (NSCLC) as an example of an excluded indication and states that effectiveness for other uses has not been established.

    A systematic review of germline testing in apparently sporadic pheochromocytoma/paraganglioma (SPP) found an overall germline mutation frequency of about 11–13%. The review tested for multiple genes including RET but found the most common mutations were in SDHB. The authors noted there were limited outcome data, concluding that the value (benefit vs harm) of germline testing in SPP patients and their family members is unknown because the balance of potential benefits and harms remains unclear.

    RET germline testing is not medically necessary / considered experimental and investigational for indications outside the policy’s listed high‑risk criteria. The policy specifically identifies routine RET testing in non‑small cell lung cancer as an example of a non‑covered use and indicates testing for other unlisted clinical scenarios lacks established effectiveness.

    Specific Indications Covered

    inv-23: First-degree relative with MTC — coverage criteria node

    First-degree relative with MTC: Member has a first-degree blood relative (parent, full-sibling, or child) with medullary thyroid carcinoma (MTC).

    Meets one of the high-risk criteria for germline RET testing.

    inv-24: First- or second-degree relative with known germline RET mutation (test for specific familial mutation)

    Known familial RET mutation in first- or second-degree relative: Member has a first- or second-degree blood relative with a known germline RET mutation — testing should target the specific familial mutation (test for specific familial mutation).

    Second-degree relatives include aunt, uncle, grandparent, grandchild, niece, nephew, or half-sibling.

    inv-25: Personal history of listed conditions (C-cell hyperplasia; two or more endocrine tumors; Hirschsprung disease; MTC; paraganglioma; parathyroid carcinoma; pheochromocytoma)

    Billing Codes and Status

    Covered CPT Codes (if selection criteria met)CPTCovered
    81404Molecular pathology procedures
    81405Molecular pathology procedures
    81406Molecular pathology procedures
    88271Molecular cytogenetics; DNA probe, each (e.g., FISH)
    HCPCS codes not covered for some indicationsHCPCS
    S3840DNA analysis for germline mutations of the RET proto-oncogene for susceptibility to multiple endocrine neoplasia type 2
    Covered ICD-10 Codes (if selection criteria met)ICD-10Covered
    C73Malignant neoplasm of thyroid
    C74Malignant neoplasm of other endocrine glands
    E07.0Hypersecretion of calcitonin
    Q43.1Hirschsprung's disease
    Z80.8Family history of malignant neoplasm of other organs or systems [thyroid cancer]
    ICD-10 Codes not covered for indications in this CPBICD-10Not Covered
    C34.00-C34.92Malignant neoplasm of bronchus and lung [non-small cell lung cancer]
    C75.5Malignant neoplasm of aortic body and other paraganglia
    D35.6Benign neoplasm of aortic body and other paraganglia
    D44.7Neoplasm of uncertain behavior of aortic body and other paraganglia

    Provider Responsibilities and Authorization

    Prior Authorization

    Prior authorization required for RET testing billed with specified CPT/HCPCS codes

    Prior authorization is required when billing molecular pathology CPT codes 81404-81406, molecular cytogenetics code 88271, or the RET-specific HCPCS code S3840; coverage is allowed only if the policy's selection criteria are met.

    • CPT: 81404, 81405, 81406
    • CPT: 88271
    • HCPCS: S3840
    Prior Authorization

    Policy history provided; no other mandatory prior-authorization process specified

    Policy history and review dates are listed (effective 03/18/1999; last review 05/08/2023; next review 03/14/2024), but no additional mandatory prior-authorization process or codes beyond those above are specified in these excerpts.

    • Effective: 03/18/1999
    • Last Review: 05/08/2023
    • Next Review: 03/14/2024

    Member Eligibility and Scope

    No additional eligibility requirement nodes were specified for this policy beyond the listed medical‑necessity criteria and documentation expectations; eligibility is determined by meeting one of the high‑risk indications described elsewhere in the policy.

    There are no separate top‑level eligibility requirement items beyond the coverage criteria. Clinical documentation must demonstrate that the member satisfies one of the policy’s high‑risk indications to support testing.

    The policy does not specify additional standalone eligibility rules; coverage is contingent on meeting the enumerated medically necessary indications and providing the required clinical justification.

    Key Definitions

    First-degree relative — Parent, full-sibling, or child.
    DefinitionParent, full-sibling, or child.
    ContextUsed in policy to define eligibility for germline RET testing when a first-degree relative has medullary thyroid carcinoma (MTC).
    Example in criteriaMembers who have first-degree blood relatives (ie, parent, full-sibling, child) with MTC meet a high-risk criterion for testing.
    Second-degree relative — Aunt, uncle, grandparent, grandchild, niece, nephew, or half-sibling.
    DefinitionAunt, uncle, grandparent, grandchild, niece, nephew, or half-sibling.
    ContextSecond-degree relatives with a known germline RET mutation can prompt testing of the member for the specific familial mutation.

    Clinical and Scientific Background

    Multiple endocrine neoplasia type 2 (MEN2) — including MEN2A, MEN2B and familial medullary thyroid carcinoma (FMTC) — is caused by germline RET mutations and predisposes individuals to medullary thyroid carcinoma (MTC) and other endocrine tumors. Germline RET testing can identify at‑risk individuals, inform risk‑reducing management such as prophylactic thyroidectomy, and help distinguish familial from sporadic MTC; sequencing of the RET gene is the principal testing strategy referenced in the policy.

    Services Considered Not Medically Necessary / Not Covered

    Germline RET testing is not covered for clinical indications outside the policy’s defined medically necessary list. The policy states that testing for germline RET point mutations is considered experimental and investigational and thus not covered for other uses, explicitly listing non‑small cell lung cancer (NSCLC) as an example of a non‑covered indication.

    A systematic review addressing germline testing in apparently sporadic pheochromocytoma/paraganglioma found that while germline mutations were identified in about 11–13% of cases, little outcome data were available to assess clinical benefit. The reviewers therefore concluded the value of germline testing in SPP patients and their families is unknown, given the uncertain balance of benefits and harms.

    Policy Summary
    PayerAetna
    PolicyRET Proto-Oncogene Testing
    Policy CodePolicy 0319
    Change TypeNo material change
    Effective DateMar 18, 1999
    Last ReviewMay 8, 2023
    Next Review DateMar 14, 2024
    Key ActionObtain prior authorization when billing the listed molecular pathology or related procedure codes and document that the member meets one of the specified high‑risk criteria.
    SourceLink
    On This Page
    Coverage and Medical Necessity CriteriaSpecific Indications CoveredBilling Codes and StatusProvider Responsibilities and AuthorizationMember Eligibility and ScopeKey DefinitionsClinical and Scientific BackgroundServices Considered Not Medically Necessary / Not Covered
    Personal history of listed conditions: Member has any of the following personal history findings: C-cell hyperplasia; two or more endocrine tumors; Hirschsprung disease; medullary thyroid carcinoma (MTC); paraganglioma; parathyroid carcinoma; or pheochromocytoma.

    Presence of any one of these conditions meets a high-risk criterion for germline RET testing.

    inv-26: Diagnostic germline testing for members with apparently sporadic MTC

    Diagnostic germline testing for apparently sporadic MTC: Diagnostic germline testing for point mutations in the RET gene is medically necessary for members with apparently sporadic medullary thyroid carcinoma.

    Used to distinguish sporadic versus familial disease; sequencing of the RET gene may be considered.

    inv-27: Hereditary MTC, MEN2 syndromes, and evaluation in patients with pheochromocytoma/paraganglioma where germline mutation testing is considered.

    Hereditary MTC, MEN2, and evaluation in PCC/PG: Germline RET testing is indicated in the evaluation of hereditary medullary thyroid carcinoma and multiple endocrine neoplasia type 2 (MEN2) syndromes, and may be considered when evaluating patients with pheochromocytoma/paraganglioma as part of assessing for hereditary syndromes and management planning.

    RET testing is commonly used for risk evaluation and to guide prophylactic thyroidectomy in MEN2 families; in pheochromocytoma/paraganglioma, the value of testing in apparently sporadic cases is uncertain but germline mutations have been reported (approximately 11–13% overall in reviewed studies).

    Documentation Required

    Incorporate genetic counseling into testing and management

    Genetic counseling is referenced as part of the testing and management pathway and should be integrated into clinical decision-making surrounding RET testing and subsequent interventions.

    • Pre-test and post-test counseling are implied before family members undergo prophylactic surgery.
    • Guidelines and recommendations about genetic cancer risk assessment and counseling are referenced.
    Step Therapy

    No step therapy requirements

    No step therapy requirements are described in the policy excerpts.

    Documentation Required

    Document clinical justification that member meets a listed high‑risk indication

    Clinical documentation must demonstrate that the member meets one of the policy's high‑risk criteria (first‑degree relative with MTC; first‑ or second‑degree relative with a known RET mutation; or personal history of C‑cell hyperplasia, two or more endocrine tumors, Hirschsprung disease, MTC, paraganglioma, parathyroid carcinoma, or pheochromocytoma).

    • Evidence that member meets any one of the listed high‑risk indications.
    • Sequencing of the RET gene may be considered per testing strategy.
    Documentation Required

    Include indication, family history, and sporadic‑tumor classification in documentation

    Clinical records should include the indication for testing (for example, medullary thyroid carcinoma, MEN2, pheochromocytoma/paraganglioma), relevant family history, and whether the tumor is classified as sporadic per the policy's definition.

    • Indication (e.g., MTC, MEN2, pheochromocytoma/paraganglioma).
    • Family history details (first- or second‑degree relatives, known familial RET mutation).
    • For pheochromocytoma/paraganglioma, documentation whether tumor meets SPP definition: absence of family history, absence of syndromic features, absence of bilateral disease, and absence of metastatic disease.
    Denial Risk

    Coverage limited to specified medically necessary indications; other uses are investigational

    Testing for germline RET point mutations is considered experimental and investigational (not covered) for indications other than the policy's listed medically necessary indications (example: non‑small cell lung cancer).

    • Do not bill/seek coverage for RET germline point‑mutation testing for indications outside the high‑risk list (e.g., routine testing in NSCLC) without documentation meeting policy criteria.
    Note

    No additional authorization/denial procedures specified in excerpts

    The excerpts do not specify explicit authorization or denial procedures or stepwise prior‑authorization steps beyond the code-based prior authorization requirement.

    Documentation Required

    Refer for genetic counseling prior to management decisions (e.g., prophylactic thyroidectomy)

    Genetic counseling is referenced as part of the process before family members who test positive undergo prophylactic surgery and should be part of care planning.

    • Counseling context is cited in background and referenced guidelines.
    Note

    Follow cited guideline recommendations for genetic risk assessment and counseling

    Guidelines and counseling recommendations are cited; incorporate guideline‑based genetic cancer risk assessment and counseling when ordering and interpreting RET testing.

    • References include ATA guidelines and National Society of Genetic Counselors recommendations.
    Note

    Order testing as part of clinical/genetic management pathway

    Order RET germline testing in the context of genetic counseling and clinical management decisions (for example, to inform consideration of prophylactic thyroidectomy for mutation‑positive individuals).

    • Testing is intended to guide clinical management in hereditary endocrine/neoplasia syndromes.
    Note

    No specified ordering‑provider restrictions in policy excerpts

    No explicit restrictions on which provider specialty may order testing are specified in these excerpts.

    Policy usePolicy specifies first- or second-degree relatives with germline RET mutations as an indication to test for the familial mutation.
    Sporadic pheochromocytoma/paraganglioma (SPP) — Tumors classified as sporadic when there is absence of family history of pheochromocytoma/paraganglioma, absence of syndromic features, a...
    DefinitionTumors classified as sporadic when ALL of the following are absent: family history of pheochromocytoma/paraganglioma; syndromic features; bilateral disease; and metastatic disease.
    ImplicationClassification of a tumor as sporadic (SPP) was used in studies assessing frequency of germline mutations and influences interpretation of testing utility.
    Evidence noteSystematic review of SPPs applied these four criteria when identifying studies of germline testing; frequency estimates and value of testing were derived using this definition.